LB Pharmaceuticals Launches Phase 2 Trial of LB-102 for Bipolar Depression Following Positive Schizophrenia Results
Key Insights
LB Pharmaceuticals (search) has initiated the Phase 2 ILLUMINATE-1 trial evaluating LB-102, a novel once-daily oral small molecule, in 320 patients with bipolar depression (search) across 30 U.S. sites.
The trial follows positive Phase 2 results in acute schizophrenia (search) where LB-102 demonstrated statistically significant benefits versus placebo with low rates of extrapyramidal symptoms and minimal sedation.
LB-102 is a potent and selective antagonist of D2, D3, and 5HT7 (search) receptors, potentially becoming the first benzamide antipsychotic approved in the U.S. for neuropsychiatric disorders.
LB Pharmaceuticals (search) has initiated a Phase 2 clinical trial evaluating LB-102 in patients with bipolar depression (search), expanding the development program for this investigational small molecule following encouraging results in schizophrenia (search). The ILLUMINATE-1 trial represents a strategic expansion into mood disorders for the compound, which could become the first benzamide antipsychotic approved in the United States.
Trial Design and Patient Population
The Phase 2 ILLUMINATE-1 trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of two doses of LB-102 (25 mg and 50 mg once daily) in bipolar depression (search). The six-week outpatient trial will enroll approximately 320 patients with bipolar 1 depression across approximately 30 sites in the United States.
Patients will be randomized 1:1 to receive either LB-102 or placebo using a fixed- and flexible-dose design. The primary endpoint is the Montgomery–Åsberg Depression Rating Scale (MADRS)-10 at week six, with the primary statistical analysis comparing results from all patients receiving LB-102, regardless of dose, with placebo. Secondary endpoints include MADRS-6, CGI-BP, cognition, and anhedonia measures, as well as safety and tolerability assessments.
Mechanism and Clinical Profile
LB-102 is a novel, once-daily, orally administered investigational small molecule and a potent and selective antagonist of D2, D3, and 5HT7 (search) receptors. The compound is a methylated derivative of amisulpride, a widely used antipsychotic outside the U.S., and was developed to retain amisulpride's benefits while addressing its limitations. LB-102 demonstrates few off-target effects and broad therapeutic potential across psychosis and mood disorders.
"We believe LB-102's pharmacologic profile, including selective D2, D3, and 5HT7 (search) receptor antagonism and favorable tolerability observed in prior clinical trials, aligns well with the critical unmet needs in bipolar depression (search)," said Anna Eramo, Chief Medical Officer of LB Pharmaceuticals (search). "Significant opportunity exists for new therapies that can offer early onset of effect, reduced side effects such as sedation and EPS (including akathisia), and improvement in anhedonia and cognitive deficits, all of which can impact a patient's ability to function."
Positive Schizophrenia Data Supports Expansion
The bipolar depression (search) trial initiation follows positive data from a four-week placebo-controlled, double-blinded Phase 2 trial in patients with acute schizophrenia (search) announced in early 2025. In that study, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid and sustained benefit and a potentially class-leading safety profile with low rates of extrapyramidal symptoms (EPS), including akathisia, minimal sedation, and few gastrointestinal side effects. The compound also showed robust effects on cognition and negative symptoms.
"We believe the compelling results from our Phase 2 trial in acute schizophrenia (search), the heritage of clinical and real-word experience with amisulpride in the treatment of mood disorders, and our innovative fixed-flexible dose trial design can significantly derisk this program," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals (search).
Market Opportunity and Unmet Needs
Bipolar disorder (search) affects approximately 7 million patients in the United States and 40 million patients worldwide. The disorder is characterized by alternating manic and depressive states, with antipsychotic medications serving as a mainstay of therapy for bipolar depression (search) due to their ability to control depressive symptoms while preventing the emergence of mania.
Despite the availability of several branded and generic therapeutics, significant unmet needs remain including faster onset without dose titration, lower rates of adverse events, efficacy against residual symptoms including anhedonia and cognitive deficits, and improved medication adherence. Approximately 60% of patients with bipolar depression (search) experience cognitive impairment and loss of interest/enjoyment (anhedonia) despite treatment, as well as high rates of adverse events, which contribute to high rates of medication discontinuation and increased risk of relapse.
Development Timeline and Future Plans
Topline results from the Phase 2 bipolar depression (search) trial are anticipated in the first quarter of 2028. The company also plans to initiate a Phase 3 clinical trial for schizophrenia (search) this quarter, with results expected in the second half of 2027.
Additional expansion opportunities for LB-102 include major depressive disorder (search), predominantly negative symptoms of schizophrenia (search), Alzheimer's disease (search) psychosis and agitation, as well as other neuropsychiatric diseases. The broad therapeutic potential positions LB-102 as a potential mainstay of psychiatric practice if approved, offering a balanced clinical activity and tolerability profile that could provide an attractive alternative to current branded and generic therapeutics.